Alice Huai-Yu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alice Huai-Yu Li has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Amit Gulati
Department of Anesthesiology and Critical Care, Memorial Sloan Kettering Cancer Center, New York, New York, USA
1 shared publication- Amitabh Gulati
Memorial Sloan Kettering Cancer Center, New York, NY, USA
1 shared publication - Anuj Bhatia
Department of Anesthesia and Pain Management, Toronto Western Hospital, Toronto, Ontario, Canada
1 shared publication Anuj K. Aggarwal
Department of Anesthesiology Perioperative and Pain Medicine Stanford University Stanford California USA
1 shared publicationDavid Spinner
Department of Rehabilitation and Human Performance Icahn School of Medicine Mount Sinai Health System New York New York USA
1 shared publicationEinar Ottestad
Department of Anesthesiology Perioperative and Pain Medicine Stanford University Stanford California USA
1 shared publication
Latest Publications
- 20 April 2023
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 48 (6) , 312-318
Role of peripheral nerve stimulation in treating chronic neuropathic pain: an international focused survey of pain medicine experts
Interventional pain management (IPM) options for refractory neuropathic pain (NP) have recently increased with availability of peripheral nerve stimulation (PNS) equipment and expertise. Given a lack of high-quality evidence and guidelines on this topic, we sought to understand the perception of physicians with expertise in treating NP regarding IPM and the role of PNS. We emailed a survey in March 2022 to international NP experts including pain medicine physicians, researchers, and leaders of 11 professional pain societies. No representatives from vendors of PNS systems were included in the design of the survey nor as respondents. Among 24 respondents (67% of those contacted), the distal common peroneal, tibial, and sural nerves were most frequently targeted (60%) with PNS. Persistent postsurgical pain of more than 3 months was the most common indication for PNS (84%). The aggregate NP treatment algorithm in order of median rank was non-opioid medications as first line, IPM including epidural/perineural steroid injections tied with transcutaneous electrical nerve stimulation as second line, pulsed radiofrequency (RF) tied with RF ablation/denervation as third line, temporary then permanent PNS as fourth line, followed by spinal cord stimulation, opioids, cryoablation, botulinum, peripheral nerve field stimulation, intrathecal targeted drug delivery, and others. Before offering PNS, 12 respondents (50%) indicated their preference for trialing non-neuromodulation treatments for 1–3 months. Twenty-two respondents (92%) agreed PNS should be offered early in the treatment of neuropathic pain. The most common barriers to PNS use were cost, lack of high-quality evidence in support of its use, lack of exposure to PNS in training programs, and lack of familiarity with the use of ultrasound guidance. PNS appears to have an increasing role in the treatment of NP but more research is needed on the outcomes of PNS to elucidate its role.
- 20 April 2023
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 48 (6) , 312-318
Role of peripheral nerve stimulation in treating chronic neuropathic pain: an international focused survey of pain medicine experts
Interventional pain management (IPM) options for refractory neuropathic pain (NP) have recently increased with availability of peripheral nerve stimulation (PNS) equipment and expertise. Given a lack of high-quality evidence and guidelines on this topic, we sought to understand the perception of physicians with expertise in treating NP regarding IPM and the role of PNS. We emailed a survey in March 2022 to international NP experts including pain medicine physicians, researchers, and leaders of 11 professional pain societies. No representatives from vendors of PNS systems were included in the design of the survey nor as respondents. Among 24 respondents (67% of those contacted), the distal common peroneal, tibial, and sural nerves were most frequently targeted (60%) with PNS. Persistent postsurgical pain of more than 3 months was the most common indication for PNS (84%). The aggregate NP treatment algorithm in order of median rank was non-opioid medications as first line, IPM including epidural/perineural steroid injections tied with transcutaneous electrical nerve stimulation as second line, pulsed radiofrequency (RF) tied with RF ablation/denervation as third line, temporary then permanent PNS as fourth line, followed by spinal cord stimulation, opioids, cryoablation, botulinum, peripheral nerve field stimulation, intrathecal targeted drug delivery, and others. Before offering PNS, 12 respondents (50%) indicated their preference for trialing non-neuromodulation treatments for 1–3 months. Twenty-two respondents (92%) agreed PNS should be offered early in the treatment of neuropathic pain. The most common barriers to PNS use were cost, lack of high-quality evidence in support of its use, lack of exposure to PNS in training programs, and lack of familiarity with the use of ultrasound guidance. PNS appears to have an increasing role in the treatment of NP but more research is needed on the outcomes of PNS to elucidate its role.
- 18 February 2022
- Published by Wiley in Pain Practice
- Vol. 22 (5) , 508-515
Considerations in permanent implantation of peripheral nerve stimulation (PNS) for chronic neuropathic pain: An international cross‐sectional survey of implanters
Aim: Novel minimally invasive short‐term and long‐term peripheral nerve stimulation (PNS) systems have revolutionized targeted treatment of chronic neuropathic pain. We present an international survey of PNS‐implanting pain physicians to assess what factors they consider when offering permanent PNS.Methods: This cross‐sectional study consisted of a survey (Qualtrics) that was distributed to PNS‐implanting physicians in a device supplier's entire email database on November 13, 2020, with 3 weeks of response time. Physicians’ contact information in the form of their email addresses had been previously collected by the supplier upon device distribution with permission to use survey responses for research.Results: Of 2032 database physicians, 40 physicians representing 37 institutions responded to the survey. The most common application of PNS was mononeuropathic pain (57%). The most frequently targeted nerve was the suprascapular nerve (29%). 14% of physicians reported 81–100% of their implants were dual‐lead. The representative physicians ranged broadly in their most frequently targeted nerves. Although mononeuropathic pain was the most common indication for PNS, there was still varied response regarding other indications such as CRPS and post‐surgical chronic pain.Conclusion: In context of a low response rate, identifying such factors can help update the prevailing treatment algorithm for interventional therapies, assist pain physicians in better identifying which patients are the best candidates for PNS, and inform future clinical trial design on PNS efficacy.
- 18 February 2022
- Published by Wiley in Pain Practice
- Vol. 22 (5) , 508-515
Considerations in permanent implantation of peripheral nerve stimulation (PNS) for chronic neuropathic pain: An international cross‐sectional survey of implanters
Aim: Novel minimally invasive short‐term and long‐term peripheral nerve stimulation (PNS) systems have revolutionized targeted treatment of chronic neuropathic pain. We present an international survey of PNS‐implanting pain physicians to assess what factors they consider when offering permanent PNS.Methods: This cross‐sectional study consisted of a survey (Qualtrics) that was distributed to PNS‐implanting physicians in a device supplier's entire email database on November 13, 2020, with 3 weeks of response time. Physicians’ contact information in the form of their email addresses had been previously collected by the supplier upon device distribution with permission to use survey responses for research.Results: Of 2032 database physicians, 40 physicians representing 37 institutions responded to the survey. The most common application of PNS was mononeuropathic pain (57%). The most frequently targeted nerve was the suprascapular nerve (29%). 14% of physicians reported 81–100% of their implants were dual‐lead. The representative physicians ranged broadly in their most frequently targeted nerves. Although mononeuropathic pain was the most common indication for PNS, there was still varied response regarding other indications such as CRPS and post‐surgical chronic pain.Conclusion: In context of a low response rate, identifying such factors can help update the prevailing treatment algorithm for interventional therapies, assist pain physicians in better identifying which patients are the best candidates for PNS, and inform future clinical trial design on PNS efficacy.